Single-center non-randomized prospective phase II study evaluating the effectiveness of induction chemoimmunotherapy in the combined outcome of locally advanced non-small cell lung disease

Cover Page

Cite item

Full Text

Abstract

This study presents the experience with induction chemoimmunotherapy (iCIT) in patients with stage III borderline resectable non-small cell lung cancer (NSCLC).

References

  1. Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, Москва. 2023; 254.-URL: https://oncology-association.ru/wp-content/ uploads/2024/06/sop-2023-elektronnaya-versiya.pdf. [The state of oncological care for the population of Russia in 2022. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. P.A. Herzen Moscow Oncology Research Institute — branch of the National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation, Moscow. 2023; 254.-URL: https://oncology-association.ru/wp-con tent/uploads/2024/06/sop-2023-elektronnaya-versiya. pdf (In Rus)].
  2. Petrella F., Rizzo S., Attili I., et al. Stage III non-small-cell lung cancer: An overview of treatment options. Current On cology. 2023; 30(3): 3160–75.-DOI: http://doi.org/10.3390/ curroncol30030239.-URL: https://www.mdpi.com/1718- 7729/30/3/239.
  3. Bonanno L., Attili I., Pavan A., et al. Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice. Crit Rev Oncol Hematol. 2021; 163: 103378.-DOI: http:// doi.org/10.1016/j.critrevonc.2021.103378.
  4. Forde P.M., Spicer J., Lu S., et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022; 386 (21): 1973–85.-DOI: http://doi.org/10.1056/NE JMoa2202170.
  5. Cottrell T.R., Thompson E.D., Fordeet P.M., al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann On col. 2018; 29 (8): 1853–60.-DOI: http://doi.org/10.1093/ annonc/mdy218.
  6. Doerr F., Stange S., Michel M., et al. Stage I and II small cell lung cancer — new challenge for surgery. Lung. 2022; 200(4): 505–12.-DOI: http://doi.org/10.1007/s00408-022- 00549-8.
  7. Zhang Q., Shao L., Tian J., et al. Stereotactic body radiation therapy or surgery for stage I–II non-small cell lung cancer treatment? — Outcomes of a meta-analysis. Transl Cancer Res. 2019; 8(4): 1381–94.-DOI: http://doi.org/10.21037/ tcr.2019.07.41.
  8. Strauss G.M. Induction chemotherapy and surgery for early-stage non–small-cell lung cancer: What have we learned from randomized trials? Journal of Clinical Oncol ogy. 2012; 30(2): 128–31.-DOI: https://doi.org/10.1200/ jco.2011.39.7570.
  9. Pisters K.M.W., Vallières E., Crowley J.J., et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer: Southwest Oncolo gy Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010; 28(11): 1843–9.-DOI: https://doi. org/10.1200/jco.2009.26.1685.
  10. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic re view and meta-analysis of individual participant data. Lancet. 2014; 383(9928): 1561–71.-DOI: https://doi.org/10.1016/ s0140-6736(13)62159-5.
  11. Stenger M. CheckMate 816: Neoadjuvant nivolumab plus chemotherapy in resectable NSCLC. HSP News Service, L.L.C. 2022.-URL: https://ascopost.com/news/april-2022/ checkmate-816-neoadjuvant-nivolumab-plus-chemo therapy-in-resectable-nsclc/.
  12. Provencio M., Nadal E., González-Larriba J.L., et al. Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2023; VOPROSY ONKOLOGII = PROBLEMS IN ONCOLOGY. 2025;71(6) 1323 КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ / CLINICAL RESEARCH 389(6): 504–13..-DOI: https://doi.org/10.1056/nej moa2215530.
  13. Palmero R., Vilariño N., Navarro-Martín A., Nadal E. In duction treatment in patients with stage III non-small cell lung cancer. Transl Lung Cancer Res. 2021; 10(1): 539–54.- DOI: https://doi.org/10.21037/tlcr-20-420.
  14. Wakelee H., Liberman M., Kato T., et al. Perioperative pembrolizumab for early-stage non–small-cell lung cancer. N Engl J Med. 2023; 389(6): 491–503.-DOI: https://doi. org/10.1056/nejmoa2302983.
  15. Cascone T., Awad M.M., Spicer J.D., et al. LBA1 Check Mate 77T: Phase III study comparing neoadjuvant nivolum ab (NIVO) plus chemotherapy (chemo) vs neoadjuvant pla cebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Ann Oncol. 2023; 34: S1295.-DOI: https://doi. org/10.1016/j.annonc.2023.10.050.
  16. Antonia S.J., Villegas A., Daniel D., et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017; 377(20): 1919–29.-DOI: https://doi. org/10.1056/nejmoa1709937.-URL: https://www.nejm. org/doi/full/10.1056/NEJMoa1709937.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2025 Problems in Oncology

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).